Clinical Trial Update: A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction [Phase 2]

View source ↗

Summary

A Phase 2 open-label pilot study evaluating MYK-461 in symptomatic hypertrophic cardiomyopathy with left ventricular outflow tract obstruction has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy
• Left Ventricular Outflow Tract Obstruction

Drugs mentioned

• MYK-461 (mavacamten)

Snippet

Sponsor: MyoKardia, Inc. | Conditions: Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction | Phase 2 | Status: COMPLETED | Results posted: 2020-02-05